期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

儿童胃肠道外间质瘤一例报告 被引量：1

原文传递
导出
摘要 胃肠道外间质瘤（extra-gastrointestinal stromal tumors,EGIST）是指来源于网膜、肠系膜或腹膜后的软组织,且与肠壁及消化道浆膜面无关的一种非定向分化的间叶源性肿瘤。EGIST在临床较少见,好发于中老年人,原发部位以肠系膜和大网膜多见,我院最近收治1例年仅4岁的发生于腹壁的EGIST患儿,现报告如下。
作者 陈志
机构地区 湖南航天医院普外科
出处 《中华普外科手术学杂志（电子版）》 2011年第4期64-64,共1页 Chinese Journal of Operative Procedures of General Surgery(Electronic Edition)
关键词 胃肠道间质肿瘤 儿童 学龄前
分类号 R735 [医药卫生—肿瘤]
  • 相关文献

参考文献2

二级参考文献35

  • 1Joensuu H,Roberts PJ,Sarlomo-Rikala M,et al.Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.N Engl J Med,2001,344(14):1052-1056.
  • 2van Oosterom AT,Judson IR,Verweij J,et al.Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors:a report of the EORTC Soft Tissue and Bone Sarcoma Group.Eur J Cancer,2002,38 Suppl 5:S83-S87.
  • 3Verweij J,van Oosterom A,Blay JY,et al.Imatinib mesylate (STI-571 Glivec,Gleevec) is an active agent for gastrointestinal stromal tumours,but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target.Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.Eur J Cancer,2003,39(14):2006-2011.
  • 4Blanke CD,Demetri GD,von Mehren M,et al.Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.J Clin Oncol,2008,26(4):620-625.
  • 5Verweij J,Casali PG,Zalcberg J,et al.Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib:randomised trial.Lancet,2004,364(9440):1127-1134.
  • 6Blanke CD,Rankin C,Demetri GD,et al.Phase III randomized,intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase:S0033.J Clin Oncol,2008,26(4):626-632.
  • 7Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST).Comparison of Two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors:a meta-analysis of 1,640 patients.J Clin Oncol,2010,28(7):1247-1253.
  • 8Blay JY,Le Cesne A,Ray-Coquard I,et al.Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year:the French Sarcoma Group.J Clin Oncol,2007,25(9):1107-1113.
  • 9Le Cesne A,Ray-Coquard I,Bui BN,et al.Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment:an open-label multicentre randomised phase 3 trial.Lancet Oncol,2010,11(10):942-949.
  • 10Heinrich MC,Corless CL,Demetri GD,et al.Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.J Clin Oncol,2003,21(23):4342-4349.

共引文献12

同被引文献17

引证文献1

二级引证文献1

中华普外科手术学杂志（电子版）
2011年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部